

Freedom of Information Request: Our Reference CTMUHB_47_22

You asked:

I would like to request the following information with regards to primary rebates schemes that have been signed by your CCG/ Health Board in the past 12 months.

1. Are there any signed for any of the following products, and if so , which ones:

- **Insulins (basal, bolus and premix)**
- **GLP-1 (i.e Trulicity)**
- **DPP-IV (i.e Januvia or Onglyza)**
- **SGLT-2 (I.e Invokana)**
- **Growth Hormones (norditropin; omnitrope; Genotropin; humatrope; nutropinAq; Saizen)**

Please see response to question 2.

2. What are the start and finish dates (or ongoing if open ended)?

Please see information provided in the table below:

	PRODUCTS	START	FINISH
INSULINS	Apidra Insuman Lantus Toujeo	June 2021 June 2021 June 2021 June 2021	March 2022 March 2022 December 2022 March 2022
GLP-1	Saxenda	March 2021	
DPP IV	None		
SGLT-2	none		
GROWTH HORMONES	Omnitrope SurePal	Sep 2021	June 2024

3. Which rebates are independent? or are they aligned to PrescQIPP?

Not applicable in Wales. There is a National process in Wales.

4. What is the total number of primary rebate schemes (any included) that your CCG/ Health Board has signed?

56 current rebates.

Rebates are handled by the All Wales Drug Contracting Committee and [NHS Wales Shared Services Partnership](#) (NWSSP), whom provides NHS procurement services on an All Wales basis.

If further information is required, please contact them directly via the following email address: shared.services@wales.nhs.uk